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After the Genome IV
Envisioning Biology in the Year 2010
The After the Genome meetings were started in 1995 to help the biological
community think about and prepare for the changes in biological research in the
face of the oncoming flow of genomic information. The term "After the
Genome" refers to a future in which complete inventories of the gene products
of entire organisms become available.
The organizers, Roger Brent, SusanBurgess, Thomas Meade, and Chris Sander,
intend to distinguish this meeting by bringing together intellectuals from subject
fields far outside of conventional biology with the expectation that this will
focus researchers beyond the immediate future. Hence the subtitle for this
year's meeting, "Envisioning Biology in the Year 2010".
Accordingly, the organizers are bringing together a broadly multi-disciplinary
group of thinkers and working scientists. The participants include biological
researchers and information workers as well as some visionary intellectuals and
executives from the computer industry,, high ranking officials from government
agencies, reporters who chronicle biology with a long-term perspective,
representatives of philanthropic organizations who are in a position to spend
money flexibly to catalyze organizational change, and eminent intellectuals
from other disciplines.
This year, the meeting will deal with four themes:
• new technologies relevant to post-genomic data collection in the first session
chaired by Thomas J. Meade of the California Institute of Technology.
• their integration into deducing events at the level of the single in the second
session chaired by Roger Brent of the Molecular Sciences Institute.
• unconventional informatic techniques for extracting meaning from this data
in the third session chaired by Chris Sander of Millenium Pharmaceuticals.
and an attempt to envision how these approaches will impact organismic
biology, and more speculatively, ecology and evolution in the final session
chaired by Susan Burgess of Structural Bioinformatics, Inc. ("
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Plenary Session
4:00 PM
5:00 PM
Registration
Social Hour _Re_istrauon Open)
6:00 PM Dinner Buffet Explorers Room
Saturday, October 10: Session I E.rtvlore.r,r R_)e2m
7:30 PM Thomas J. Meade. California [nstitute of Technology
Susan K. Burgess, Structural Bioinformatics. Inc.
Welcome.
7:45 PM Ro_er Brent. Molecular Sciences institute
[nrroducrioa co A TG IV.
8:00 PM Dan Janzen. University of PennsyLvania
Biodiversir_. Development of a Large Dopical Conserved Wiidland.
Area de Con.vem'acion Guanacasre.
8:45 PM Stephen Grand. Cvberiife Technology
The Bio/o,¢y of an Ai,en Species." How Ceils Make Souls.
9:30 PM Reception
1,0:00 PM Discussion Session
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Cross-Disciplinary Technologies for Post-Genomics
Thomas J. Meade. Session Chair
7:00 - 8:25 AM Breakfast Buffet Mur_zi Di::m'.. R, ,<.n
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Thomas J. Meade. California Institute of Technology
8:45 AM Jeff Bvers. Naval Research Labs
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9:30 ,a3,I Chad Mirken. Northwestern University
Ultraselec:ive DNA Detection 3,lethods Based Upon ,rove! .Vcznor_,c:,'rzc:'c
Probes.
t0:15 AM Allen North.cup. Cephiad. Inc.
Next Generation of Gene Amplification and Detection Tec/moio,e:e_.
I 1:00 - 11:45 Break
Sunday, October if Session 2 E.'c,.vt'ot_'rs Room
[ 1:45 AM Rob Carlson. Molecular Sciences Institute
Doing Biology with Microfabricated Micrqfluidic Devices.
t2:30 PM David Soane. Alnis, Inc.
Synthetic Poivmer Complements and their Applications.
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continued
Cross-Disciplinary Technologies for Post-Genomics
Thomas J. Meade. Session Chair
1:15 - 2:30 PM Luncheon Dell Buffet Mural Dining Room
2:30 - 5:00 PM Afternoon Activities
5:00 PM Social Hour - Micro Brew Bar Exp io re rs ?a rio
6:00 PM Western BBQ Dinner E.vpiorers Room
Sunday. October i I Session 3 E.vptorers Room
7:30 PM Tom Tutlius. Boston University
Making Large-Scale Maps oj"DNA Smmt,tre in Gene Conrroi Re',,enrs.
8:L5 PM Raoul Kopieman. University of Michigan at Ann Arbor
Usin;, ,Vwzopebbles ro Interrogate Living Ceils.
9:00 PM Posters and Reception
t0:00 PM Discussion Sessions
Monday
12 October 1998
Cellular Components and Pathway Analysis/Modeling
Roger Brent, Session Chair
7:00- 8:25,4aM Breakfast Buffet Mural Dining Room
Monday. October I2: Session [ Explorers Room
8:00 AM Introduction by Session Chair
Roger Brent, .Molecular Sciences Institute
8:t5 AM
9:00 ,aaM
Bill Hutchens. Ciphergen
Extracting bLrbrmation from Biological Systems with Solid Phase
Fracriona:ion Time of Flight Mass Specn'ometr?:.
Dennis Bray. University of Cambridge
Sparical Organization and the Logic of Signal Transduction Pathways.
9: 45 .a2vl Drew End,.. E-ni;'ersitv of Wisconsin at Madison
E.rperimenrat Characterizations of Altered Generic E&men: Order on the
T7 Growth Cvc!e.
[0:30 - 10:45 AM Short Break
Monday. October t.2: Session 2 Expiorers Room
t0:45 AM John Weinstein. NIH. NCI
hgbJvmztion-intensive Drz,g Discoverw." Genomics, Prereomics. and
Bioinfonnatlcs.
[ i:30 PM Yehoshua Bruck. California Institute of Technology
Gene Re;,uianon. ,4svnchrono,ts Computing and Sroc'hasric Comverir_(;n.
Monday
12 October 1998
continued
Cellular Components and Pathway Analysis Modeling
Roger Brent, Session Chair
12:15 PM Boxed Lunches To Go
Depart for Yellowstone National Park Excursion
Expiorers Room
Chartered Bus
12:[5 - 5:00 PM Afternoon Tour of Yellowstone Yellowstone National Park
5:00 PM Yellowstone National Park Dinner cg[a' Fairhzid hm
6:30 PM Depart Old Faithful Inn Chartered Bus
Monday. October 12: Session 3 Explorers Room
8:00 PM Kathe_n Resing. University of Colorado
Cefluhzr Function Information from Protein Mass Specrromen_.'.
8:45 PM Guri Giaever. Stanford University
Drug,-h,:uced Huploinsufficiency: ,4 Genomic Approach ro Dru,, Y_t:ger
Identification.
9:30 PM Posters and Reception
10:00 PM Discussion Sessions
Tuesday
13 October 1998
Syntax for IntraceIlular Signalling and Integrated Bioinformarics
Chris Sander, Session Chair
7:00 - 8:25 AM Breakfast Buffet ,_,h.al Dinine Room7
Tuesday. October 13 Session t E.vplorers Room
8:30 ,-MM Introduction by Session Chair
Chris Sander. Millenium Pharmaceuticals
8:45 ANI Tom Patterson. Entelos, Inc.
Modelling Physiology at the Organ-system Level
9:30 AM 3elf Skolnick. Scripps University
Large Scale Structure Prediction.
10:15 - 1 i:00 Break
Tuesday, October t3 Session 2 E,vplorers Room
i i:00 AM Barry kIonig, Columbia University
Srrtlcture-based Analysis or Seq,ence and Ftmcrion.
l 1:45 AM Jeff Saffer. Battelle-Pacific Northwest
/-.,r.seof C, mte.'cr Vectors Analysis of Large Volumes or Biological Data.
12:30 - 14-5 PM Fish Fry Luncheon E.v.plorer,_ P_zrio
Tuesday
13 October 1998
continued
Syntax for Intracellular Signalling and Integrated Bioinformatics
Chris Sander. Session Chair
1:45 - 6:00 PM Afternoon .*ctivities
6:00 PM Dinner Mural Dimng Room
7:30 PM
Tuesday. October [3: Session 3 Explorers Room
Anna Tsao, DARPA
Mathematical Approaches to Dealing with the Curse of Dime,zsio_raiirT., in
DepartTnent of Defense Signal Processing Applications.
8:15 PM Tom Schneider. NIH. NCI
Molecular h_jblwTation Theom,. From Clinical Applications ro 5Io;ec,d_zr
Machine Efficiency.
9:00 PM Posters and Reception
t0:00 PM Discussion Sessions
Wednesday
14 October 1998
Biodiversi_/trans-species Inference Leading to
an Enlightened Biology
Susan Burgess, Session Chair
7:00 - 8:25 AM Breakfast Buffet Murai Dining Room
Wednesda;'. October [4: Session t Explorers Room
8:30 AM
8:45 AN[
Opening Remarks by Session Chair
Susan K. Burgess. Structural Bioinformatics, Inc.
James Shapiro. University of Chicago
Natural Generic Engingeering of Genome System Architecture m Evolution.
9:30 AM Lee Eiden. NIH
Cross-species Pathway Comparison, Pha_vnacotogicai Dissections.
[0:I5 AM Greg Benford. University of California at Irvine
Fixing dTe Greenhouse.
l l:O0 Boxed Lunches Available
l I:00 Meeting Adjourned
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BIODIVERSITY DEVELOPMENT
OF A LARGE TROPICAL CONSERVED WILDLAND:
AREA DE CONSERVACION GUANACASTE.
...._j
D. Janzen and W. Hallwachs
University of Pennsylvania, Philadelphia, PA 19104
Dj anzen @ sas.upenn.edu whallwac @ sas.upenn.edu
The only chance that tropical w.ildlands have of surviving into perpetuity is
through integration with the human genome, through their being peacefully positioned
somewhere within the three major human activities - sex, shelter and food. The Area de
Conservacion Guanacaste in northwestern Costa Rica is a working pilot project aimed at
this integration, otherwise known as Biodiversity Development or the gardenification of
nature. We discuss the technical, sociological, economic and political aspects of such an
act.
BIOLOGY OF AN ALIEN SPECIES:
HOW CELLS MAKE SOULS.
$. Grand
Cyberlife Technology
Quayside Bridge Street, Cambridge, CB4 8AB
Stephen._and@cybeflife.co.uk
UK
In general, Biology at the macro level has been obliged to try and understand
complex, ready-built organisms, for which no instruction manual exists. Genes and
outward behavior can be correlated, but mechanisms by which the former lead to the
latter are usually opaque, especially when the behavior is high level. An alternative
approach is to play at being a god. Armed with enthusiasm and a small selection of
basic, biologically plausible building blocks, can we synthesize a complete organism that
exhibits high-level behaviors such as learning, courtship, and curiosity? Can such
learning by putting things together offer insights that learning by taking things apart has
so far failed to do?
Will the future creation of intelligent artificial life forms constitute a new branch
of biotechnology? A useful discussion in the space of forty-five minutes is a tall order,
so to avoid disappointment you might wish to know the answers in advance. They are:
yes, perhaps, and probably.
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CONTROLLING BIOSYNTHETIC PATHWAYS
WITH lVlAGNETOELECTRONICS
J. M. Bvers
Materials Physics, Code 6344, Naval Research Laboratory Washington, D.C. 20375
and Department of Physics, George Washington University, Washington, DC
Tel. (202) 767-6147 FAX (202) 767-1697 E-Mail byers@foucault.nrl.navy.rml
Rapid development of small-scale magnetic structures for use as sensors,
nonvolatile memory elements and localized magnetic field sources has provided a new
technology within the last ten years called magnetoelectronics. This new form of
electronics is being adapted to more traditional silicon-based electronics in the
semiconductor industry. Our aim is to adapt this technology for use in biological
applications. Using magnetoelectronics to couple to biological systems is compelled by
the ability of magnetism to function within a saline solution but not interfere with
biochemical processes. The talk will show how magnetoelectronics has been used in
biosensors and could control biosynthetic pathways via biologically functionalized
magnetic nanoparticles. The ultimate goal is explore how to create a kind of
biomolecular electronics that could exist in a layered IC geometry, or 'chip' package
without the need for optical coupling but instead a magnetoelectronic interface. The role
of genomics in creating biomolecular electronics will also be addressed.
This work is supported by the Office of Naval Research (ONR) and the Defense
Advanced Research Projects Agency (DARPA).
ULTRASELECTIVE DNA DETECTION METHODS
BASED UPON NOVEL NANOPARTICLE PROBES.
C. A. Mirkin
Northwestern University, Department of Chemistry, 2145 Sheridan Road,
Evanston, IL 60208
Camfl-kin @ che m.nwu.edu
New detection methods for DNA and RNA, which are based upon novel
oligonucleotide functionalized nanoparticles, will be described. These methods rely on
the difference in properties between dispersed particles and those assembled into
extended periodic materials by hybridization with complementary target molecules. The
extraordinary, selectivity exhibited by one such system based upon Au nanoparticles will
be described. This system allows one to colorimetrically detect a DNA sequence with
near perfect selectivity at femtomole target levels. The origin of this selectivity and
relationship to the novel approach of using nanoparticle-based materials for DNA
detection will be discussed. The prospect of using these systems for high selectivity and
sensitivity point-of-site assays will be addressed.
NEXT GENERATION OF GENE AMPLIFICATION
AND DETECTION TECHNOLOGIES.
M. A. Northrup
Cepheid, 1190 Borregas Avenue, Sunnyvale, CA 94089-1302
Northrup @cepheid.com
Future nucleic-acid-based diagnostic instruments need improvement over the
current state-of-the-art. Increasing the speed and sensitivity of the assays, while reducing
costs are clear goals. Recently, it has become possible to microminiaturize fluidic and
sensing components using micromachining and precision injection molding. There has
been a large amount of interest and effort in the area of miniaturization of such systems,
yet not all of the properties of fluidics and sensing methods improve as they axe
drastically reduced in size. It is clear that implementing miniaturized diagnostic
instruments is not a matter of simply "shrinking" their conventional counterparts, nor of
automating existing manual procedures. What is required to harness the full potential of
scaling technologies is the use of design methods that take into account scaling effects
and the development of completely new processing approaches. In particular, we will
discuss sample preparation and detection approaches in this context.
DOING BIOLOGY WITH
MICROF.&BRICATED MICROFLUIDIC DEVICES.
R. Carl_on
The Molecular Sciences Institute, 2168 Shattuck Avenue, Berkeley, CA 94704
Rcarlson @ sequence.molsci.org
As biology proceeds beyond sequencing genomes to exploring phenotypic
implications of expression and engineering DNA, it will be useful to physically
manipulate single cells and their contents. This style of measurement and experiment
requires tools on the same length scale as the cells themselves. Towards this end, several
decades worth of experience in building integrated circuits can be utilized to control
geometries at the micron level, providing for conception and construction of a new
microfluidic toolbox. Selecting a single cell from a population and probing its
biochemical state or genome are ideal applications of microfabrication.
SYNTHETIC POLYMER COlVIPLEMENTS
AND THEIR APPLICATIONS.
D. $oane
Alnis, LLC. 1933 Davis Avenue, Suite 266, San Leandro, CA 94577
soane @ ix.netcom.com
A new approach has been developed to synthesize molecular complements that
precisely map the size, shape, and surface characteristics of selected molecules or entities
(the targets). Such synthetic polymer complements (SPCs) are unique in that they possess
molecular dimensions, thus offering several opportunities worthy of detailed scientific
exploration. Alnis has studied the potential of SPCs for enzyme stabilization in non-
aqueous and elevated-temperature environments via molecular scaffolding. Specially
prepared SPCs may be used to recognize and sequester contaminants or infectious agents
from mixed fluids. SPC-target conjugates also hold the promise for the delivery, of
therapeutic agents that are intrinsically fragile or difficult to uptake. Finally, the SPCs
themselves may exhibit biological and pharmacological activities as a result of their
affinity toward selected targets.
MAKING LARGE-SCALE MAPS OF DNA STRUCTURE
IN GENE CONTROL REGENTS.
T. Tuilius
Boston University, Department of Chemistry, 590 Commonwealth Avenue,
Boston, MA 02215
USING NANOPEBBLES TO INTERROGATE
LMNG CELLS.
R. Kopelman, M. Philbert, H. Clark, and M. Hoyer
University of Michigan, Departments of Chemistry and Toxicology,
Ann Arbor, MI 48109-1055
Kopelman @umich.edu
Traditional investigations into the role of physiologic influences on normal
function and disease have been superseded by "cracking the genetic code." Since then,
quantal leaps in understanding of genetic mechanisms of disease, nucleic acid
interactions in transcription/translation, and the plethora of signal transduction
mechanisms which initiate these processes have moved to the forefront of modem
biological research. However, molecular biological research has always had as its
backdrop traditional physiology, electrophysiology and more recently patch clamping and
fluorescent microscopic approaches. Probes Encapsulated By Biologically-Localized
Embedding (PEBBLEs) and Nano Opto-Chemical Systems (NOCS) constitute the next
generation of nano-physiological tools which combine applied physics and
photochemistry with molecular biology and optical fluorescence microscopy. These new
tools may be used to gather targeted three-dimensional physiologic data in vivo, in real
time. PEBBLEs have proven useful in the detection of minute shifts of pH, nitric oxide
and calcium concentrations in compartments as small as the phagosome of a macrophage.
The incorporation of molecular recognition into NOCS hold the promise of providing
precise targeting of these sensors to specific organelles, cytoskeletal elements or
membranous boundaries of the cell. Combinations of fluorescent indicators which emit
in the visible spectrum in conjunction with reporters of enzymatic action in NOCS (e.g.,
green fluoresent protein, luciferase, etc.) will provide novel methods for precise nano-
localization of cellular critical molecular and ionic processes in the maintenance of
normal cellular funciton or the initiation and progression of disease.
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EXTRACTING INFORMATION FROM BIOLOGICAL SYSTEMS
WITH SOLID PHASE FRACTIONATION TI'ME OF FLIGHT
MASS SPECTROlVIETRY.
W. Hutchens
Ciphergen Biosystems, 490 San Antonio Road, Palo Alto, CA 94306
SPATIAL ORGANIZATION AND THE LOGIC OF
SIGNAL TRANSDUCTION PATHWAYS
D. Bray and R. Bourret
Zoology, University of Cambridge CB2 3EJ UK
Microbiology and Immunology, University of North Carolina, Chapel Hill NC 27599.
We have been investigating the pathway of intracellular signals used by coliform
bacteria in the detection of chemotacticsfimuli. The function and formation of this
pathway were examined by means of computer-based models based on physiological data
collected from single tethered bacteria of over 60 mutant genotypes. Both deterministic
and individual-based stochastic programs have been used. Quantitative discrepancies
between computer models and experimental data throw a spotlight on areas of uncertainty
in the signal r.ransduction pathway, highlighting the importance of spatial organization to
the logical operation of the pathway. In particular they emphasize the function of a
specific, well-characterized, cluster of proteins associated with the chemotaxis receptors
which acts like a self-contained computational cassette.
Most recently we examined the failure of conventional models to reproduce the
very high gain and dynamic range of the chemotactic response. This led us to propose a
mechanism in which signal amplification takes place by the probabilistic spread of
conformations in clusters of receptor complexes on the surface of the bacterium. This
mechanism, analogous to the behavior of magnetic dipoles in a spin glass, can account
quantitatively for the remarkable sensitivity and bandwidth of chemotactic detection.
Conformational spread in clusters of receptors is likely to be employed widely by cells
other than bacteria and for purposes other than chemota.xis.
EXPERIMENTAL CHARACTERIZATIONS OF ALTERED GENETIC
ELEMENT ORDER ON TI-IE T7 GROWTH CYCLE.
D. Endy and I. Molineux
University of Wisconsin at Madison, 1415 Engineering Drive, Madison, WI 53706
University of Texas at Austin, Department of Microbiology, Austin, TX 78712
Drew @:7.che.wisc.edu motineux @ mail.utexas.edu
INFORMATION-INTENSIVE DRUG DISCOVERY:
GENOMICS, PROTEOMICS, AND BIOINFORMATICS.
J. N. Weinstein
Laboratory of Molecular Pharmacology, National Cancer Institute (NCI), NIH,
Building 37, Room 5D-02, Bethesda, MD 20892
We inste in @ dtpax2, ncifcrf, go v
The current revolution in drug discovery is based largely on developments in
molecular biology and informatics. A case in point is provided by the drug discovery
program of the NCI, which has profiled more than 65,000 compounds for their activity
against 60 human cancer cell lines. The resulting patterns of activity (pharmacological
fingerprints) have proved rich in information on mechanisms of drug action and
resistance (Paull, et al., JNCI 81:1088,1989; Weinstein, et al., Science 258:447, 1992).
To characterize the 60 cell types (and selected transfectants) with respect to molecular
markers, we have done careful parallel harvests of DNA, RNA, and protein for what I
have termed "omic" analysis -- including protein expression profiling by 2-D gels and
mRNA expression profiling by high density cDNA and oligonucleotide microarrays.
The data complement those of the NCI's Cancer Genome Anatomy Project in that the 60
cell line "patients," unlike most human ones, have extensive, well-defined treatment
histories -- i.e., they have been treated with >65,000 agents one at a time and
independently (Weinstein, et al., Science 275:343, 1997).
(Many others have contributed to this work, including U Scherf, M Waltham, TG
Myers, WC Reinhold, L Smith, L Tanabe, JK Lee, D Andrews, J Buolamwini, W van
Osdol, G Li, DA Scudiero, NL Anderson, DT Ross, M Eisen, PO Brown, D Botstein, D
Shalon, E Lashkari, R Simon, L McShane, E Lander, T Golub, H Coller, P Tamayo, D
Slonum, KW Kohn, Y Pommier, EA Sausville, and the Late KD Paull.)
GENE REGULATION, ASYNCHRONOUS COMPUTING
AND STOCHASTIC COMPETITION.
J. Bruck and M. Gibson
California Institute of Technology, Mail Code 136-93, Pasadena, CA 91125
Brock@ paradise.cattech.edu
As more data become available about genetic regulatory networks, it is becoming
apparent that ad-hoc methods of describing biological systems are insufficient for
analyzing complex biochemical networks. There are two main classes of models of gene
regulation. The first class consists of very high level, qualitative models. The problem is
that it is hard to get quantitative predictions from it. The second class of models
consists of physical biochemistry. These models use low level quantitative data, such as,
binding constants, rate constants, etc. This sort of models should, in principle, give
nearly exact quantitative predictions. However, in practice, such models tend to involve
a number of thermodynamic and kinetic parameters, many of which are not known.
We will argue that these low-level details are important and can be utilized as part of our
proposed hierarchical methodology that consists of four levels of abstraction. The
lowest level is the biochemical details of expression of an individual gene. The second
level is a stochastic competition, which is basically the short term interaction between
two or more genes being expressed simultaneously. The third level of abstraction is a
probabilistic finite state machine, which puts together short term interactions into a long
term framework. The final level is the organism level, where we use the probabilistic
finite state machines to make predictions about the organism under various
manipulations. We will present theoretical results of applying the new modeling
methodology to the lysis/lysogeny decision process in Lambda phage.
CELLULAR FUNCTION INFORMATION FROM
PROTELN MASS SPECTROMETRY.
K- Resing and N. Ahn
University of Colorado, Boulder, Department of Chemistry and Biochemistry,
Campus Box 215, Boulder, CO 80309
Resing @ stripe.colorado.edu
The development of electrospray and matrix assisted laser desorption ionization
for introduction of biological samples into a mass spectrometer has greatly facilitated
analysis of proteins. The first obvious advance has been in analysis of post-translational
modifications, because it is now possible to sequence peptides in complex mixtures.
More recently, the development of protocols for data base searching using sequence from
peptides generated from in-gel digests has opened new areas of cell biology, particularly
in the new field of proteomics, the characterization of the protein compliment of a given
cell. We are using this technique to approach signal transduction from a systems analysis
viewpoint. Finally, it is seldom appreciated that mass spectrometry can provide
information on dynamic motion or conformational change in proteins by analysis of
deuterium exchange at backbone amides. Analysis of the changes detected in the
signaling kinases ERK2 (extracellular regulated kinase 2) and its activator, MKK (MAP
kinase kinase), shows that these two enzymes show fundamental differences in the
pattern of changes and that these reflect different activation strategies of each.
DRUG-INDUCED HAPLOENSUFFICIENCY:
A GENOMIC APPROACH TO DRUG TARGET IDENTIFICATION.
G. N. Giaever
Stanford University, School of Medicine, Stanford, CA 94305-5307
Ggiaever @cmgrn.stanford.edu
Alterations in gene dosage can be used as a tool for drug target identification. We
have shown that by lowering a single g enefs dosage from two copies to one copy in
diploid yeast, the resulting heterozygote is sensitized to a drug that acts on this genefs
product. This haploinsufficient phenotype thereby identifies the gene product of the
heterozygous locus as the likely drug target.
This new finding is exploited in a genomic approach to drug target identification.
Genome sequence information is used to generate molecularly tagged heterozygous yeast
strains that are pooled, grown competitively in drug, and analyzed for drug sensitivity.
using high-density oligonucleotide arrays. This approach makes it feasible to screen all
potential drug targets in yeast in a single assay.
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MODELLING PHYSIOLOGY AT THE ORGAN-SYSTEM LEVEL.
T. Patterson
Entelos, Inc. 4040 Campbell Avenue, Suite 200, Menlo Park, CA 94025
Paterson@entelos.com
LARGE SCALE STRUCTURE PREDICTION.
S. Skoinick
Scripps Research knstimte, 10550 N. Torrey Pines Road, TPC5, La Jotla, CA
Skolnick @scripps.com
92037
STRUCTURE-BASEDANALYSIS OF SEQUENCEAND FUNCTION.
B. I-Ionig
Columbia University, 221 Black Building, New York, NY
Honig@tranto.bioc.columbia.edu
10032
USE OF CONTEXT VECTORS FOR ANALYSIS OF
LARGE VOLLrMES OF BIOLOGICAL DATA
J. D. Saffer
Battelle-Pacific Northwest Labs, Richland, WA 99352
Advances in the genome era has led to many _large-scalef biological approaches
including high-throughput sequencing, gene array technology, and automated methods
for defining protein-protein interactions. Effective use of the resulting large volume of
data presents new challenges. The key issues in dealing with this data flood are (1) the
need interrogate all the data simultaneously, (2) the need for rapid analyses, and (3) the
need to integrate multiple data types. Context vectors provide one approach that
addresses these issues.
Practical use of context vectors involves three basic steps. First, the vector has to
be created based on meaningful characteristics. In this vector creation process, the type of
question being asked will determine how to create the vector. Usually, the number of
possible characteristics and iterations leads to an overwhelming computational problem.
This problem can be greatly simplified through the use of feature extraction methods.
Second, the vectors have to be visualized. This can be accomplished using a variety of
approaches, often including various clustering methods. Third, sufficient tools are
needed to interact with the visualization. It is through these interactions that discoveries
are made.
We have successfully applied context vectors to the analysis of newly discovered
proteins of unknown function. For example, a 15 minute analysis of the sequence of
predicted proteins from Methanococcus jannaschii identified a large number of putative
transport proteins that were not recognizable as such using BLAST and that other
computational methods took weeks to find. This type of analysis has been extended to
very large data sets, such as SwissProt, and demonstrates the ability of the method for
large-scale comparisons. In addition, visualization of protein sequence context vectors
was shown to provide a rapid means for comparing whole genomes.
We have also applied context vectors for the analysis of gene expression arrav
data. Traditional methods of analyzing such data rely primarily on Boolean queries,
which allow assessment of expected associations. In contrast, we have found that
visualization of array data allows discovery and exploration of unexpected relationships.
MATHEMATICAL APPROACHES TO DEALING WITH
THE CURSE OF DEMENSIONALITY IN
DEPARTMENT OF DEFENSE SIGNAL PROCESSING APPLICATIONS.
Anna Tsao
DARPA, Defense Sciences Office, 3701 N. Fairfax Drive, Arlington, VA 2203
Atsao @.darpa.mi'.
In the last few years, dramatic strides have been made in several signal processing
applications that can be characterized as having large numbers of degrees of freedom.
The experience has highlighted several principles for approaching information extraction
problems that appear to have broad generality. In this talk, these principles will be
discussed and illustrated using examples from DoD-sponsored research, primarily in
harmonic analysis-based methods.
MOLECULAR INFORMATION THEORY:
FROM CLINICAL APPLICATIONS TO
MOLECULAR MACHINE EFFICIENCY.
T. D. Schneider
National Cancer Institute, Frederick Cancer Research and Development Center,
Laber_tory of Experiments' ._.nclComputational Biology,
P. O. Box B, Frederick, hiD 21702-1201
toms@ncifcrf.gov htrp://www-lecb.ncifcrf.gov/-toms/
Information theory was introduced by Claude Shannon in 1948 to precisely
characterize data flows in communications systems. The same mathematics can also be
fruitfully applied to molecular biology problems. We start with the problem of
understanding how proteins interact with DNA at specific sequences called binding sites.
Information theory allows us to make an average picture of the binding sites and this can
be shown with a computer graphic called a sequence logo (http://www-
lecb.ncifcrf.gov/-toms/sequencetogo.html). Sequence logos show how strongly parts of
a binding site are conserved, on a scale in bits of information. They have been used to
study a variety of genetic control systems. More recently the same mathematics has
been used to look at individual binding sites using another computer graphic called a
sequence walker. Sequence walkers are being used to predict whether changes in human
genes cause mutations or are neutral polymorphisms. It may soon be possible to predict
the degree of colon cancer by this method. Information theory can also be used to
understand the relationship between the binding energy dissipated when two molecules
stick together and the amount of sequence conservation of the molecules measured in
bits. Using the Second Law of Thermodynamics, this relationship can be expressed as
the efficiency of the molecular interaction. Surprisingly, manv molecular systems
including genetic systems, visual pigments and motility proteins have efficiencies near
70%. A purely geometrical explanation of this result shows that although biological
systems are selected to have the highest efficiency, it is restricted to 70% because having
precisely distinguishable molecular states is more important.
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NATURAL GENETIC ENGINGEERING OF GENOME SYSTEM
ARCHITECTURE IN EVOLUTION.
J. Shapiro
University of Chicago, 920 E. 58 _"Street, Chicago, IL 60637
Jsha@ midwav.uchicago.edu
Molecular genetics teaches three lessons relevant to thinking about the nature of
genetic change during evolution:
(1) Genomes are organized as hierarchies of composite systems (multidomain
protein-coding sequences; functional loci made up of regulatory, coding,
processing and intervening sequences; multi-locus regulons and replicons)
interconnected and organized into specific "system architectures" by
repetitive DNA elements.
(2) Genetic change often occurs via natural genetic engineering systems (cellular
biochemical functions, such as recombination complexes, topoisomerases,
and mobile elements, capable of altering DNA sequence information and
joining together different genomic components.
(3) The activity of natural genetic systems is regulated by cellular control circuits
with respect to the timing, activity levels, and specificities of DNA
arrangements (e.g. adaptive mutation, Ty element mobility, P factor
insertions).
These three lessons provide plausible molecular explanations for the episodic,
multiple, non-random DNA rearrangements needed to account for the evolution of novel
genomic system architectures and complex multilocus adaptations. This molecular
genetic perspective places evolutionary change in the biologically responsive context of
cellular biochemistry..
CROSS-SPECIESPATHWAY COlVIPARISON,PHARMACOLOGICAL
DISSECTIONS.
L. Eiden
NIaMH, 5600 Fishers Lane Room 11-I03 Rockville, MD 20857
Eido @ codon.nih.gov
FLXING TI=IE GREENHOUSE.
G. Benford
University of Califomia at Irvine, Physics & Astronomy, 4176 FRH, Irvine, CA 92697
Gbenford@uci.edu
No issue holds more Frofound possible consequences for the next century that
greenhouse warming. Yet so far the debate and hand-wringing have been both angn'y and
unimaginative. There may very well be fairly simple fixes, even cheap ones -- but the
tone of discussion never makes this clear. Could we intervene to offset the warming?
Accept that greenhouse gases will rise and find ways to compensate for them?
Surprisingly, some schemes appear possible to deploy now, and at reasonable cost. They
could be turned on and off quickly, if we get unintended effects.
The simplest way to remove carbon dioxide from the air is to grow plants,
preferably trees. About half the U.S. CO2 emissions could be captured if we gew tree
crops on economically marginal croplands and pasture. This would cost about five billion
dollars a year. Soaking up the world's present CO2 increase would take up an Australia-
sized land area. i.e., a continent. One should compare the cost of achieving this same end
by suppressing fuel use: roughly $500 billion a year to reduce global CO2 emissions by
30%, a number easily debatable within a factor of two.
An even more direct approach promises similar savings. What could be more
intuitively appealing than simply reflecting more sunlight back into space, before it can
be emitted in heat radiation and then absorbed by _eenhouse gases? People can
understand this readily enough; black T-shirts are warmer in summer than white ones.
We could compensate for the effect of all greenhouse gas emission since the Industrial
Revolution by reflecting one percent more of the sunlight. Our upper atmosphere is a
good place to intervene, because much sunlight gets absorbed in the atmosphere on its
way to us. We already add a perfectly good reflecting area to the upper atmosphere as
part of everyday flying -- aircraft exhausts. Making the fuel mixture in a jet engine burn
rich can leave a ribbon of fog behind for up to three months, though as it spreads it
becomes invisible to the eye. These motes would also come down mostly in rain, not
troubling the brow of the EPA. Fuel costs about fifteen percent of airlines' cash operating
expenses, and running rich increases costs only a few percent. This means that for about
ten million dollars this method would offset the 1990 U.S. greenhouse emissions, quite a
cheap choice. Adding this to the cost of an airline ticket would boost prices perhaps one
percent. These ideas envision doing what natural clouds do already, as the major players
in the total albedo picture. A four percent increase in stratocumulus over the oceans
would offset global CO2 emission. Land reflects sunlight much better than the wine-dark
seas, so putting clouds far out from land, and preferably in the tropics, gets the greatest
leverage. Making clouds is an old but still controversial craft. Clouds condense around
microscopic nuclei, often the kind of sulfuric acid droplets geoengineers could spread in
the stratosphere. Clouds cover about thirty-one percent of our globe already, so a four
percentincreaseis not going to noticeablyruin anybody'sday. Tinkering with sucha
mammothnaturalprocessis daunting,but aboutfour hundredmedium-sizedcoal-fired
powerplantsgiveoff enoughsulfurin ayearto do thejob for thewholeEarth.
At first theseshouldoperateasregionalexperiments,to work outagoodmodelof
how theocean-cloudsystemresponds.Cost:abouttwo billion dollarsperyear. Simply
addingsandor glassto ordinaryasphalt("glassphalt")doublesits albedo. A 1997study
showedthatLos Angelesis five degreesF. warmerthan thesurroundingareas,mostly
due to dark roefs and asphalt.White roofs,concrete-coloredpavementsand aboutten.
billion newshadetreescouldcool thecity.belowthecountryside,cuttingair conditioning
costs eighteenpercent.It might take only a few billion dollars to mitigate the U.S.
emissionof CO2. Any geenhousefix mustacceptthat our prosperityis built upon
cheap,handyenergy,andthedevelopingnationswill notgive it up.
TOOLS AND DATABASES FOR THE ANALYSIS OF
BIOCHEMICAL REACTION NETWORKS
A. Arkin
Lawrence Berkeley National Laboratory,
Physical Biosciences Division, Berkeley, CA 94720
E-mail: aparkin@lbl.gov Web: http://www.lbl.gov/-aparkin
Biological regulatory networks are the circuitry that control cellular function and
malfunction. The chemistry underlying the function of these networks is extraordinarily
complex and difficult, if not impossible to understand knowing only a list of the parts
(genes, proteins, and other chemicals) and a list of which parts react with which other
parts. Just as when analyzing and diagnosing complex electronic circuits, mathematical
models and computational tools for analysis and simulation are necessary if we are to
understand, control and even design our own biological and genetic reaction networks. In
order to build such tools many different types of data will have to be databased in
addition to the genomic parts lists and 'network topology' specifications that are now the
most commonly used information. Physical data such as detaiIed mechanisms, kinetic
constants and data, thermodynamic parameters have to be readily available. Also
databases of phenotypic data such as gene chip data under numerous conditions, cell
morphology, cell fate maps, etc. must also be kept in order tovalidate the
model/simulations. We are developing a suite of network deduction, simulation and
analysis tools analogous to the Spice simulation/analysis tool ubiquitously used by
electrical engineers. The tool interfaces to genome databanks, pathway databases such as
EcoCyc and Kegg; and specialized databases of mechanisms, physical constants and
behavioral data in order to predict the biochemical network structure and predict and
analyze the resultant genetic/biochemical pathway kinetics as a system. Applications of
the tools to metabolic systems, microbial pathogenic systems will be briefly discussed.
COMPUTER-AIDED RESOLUTION OF AN EXPERIMENTAL
PARADOX IN BACTERIAL CHEMOTAXIS.
W. Abouhamad*, D. Bray#, M. Schuster*, K. Boesch*,
R. Silversmith*, & R. Bourret*
*University of North Carolina, Department of Microbiolog-y & Immunolog-y,
Chapel Hill, NC 27599-7290 .......
(Telephone) 919-966-2679 (FAX) 919-962-8103 emaii: bourret@med.unc.edu
Escherichia coli responds to its environment by means of a network of
intracellular reactions which process signals from membrane bound receptors and relay
them to the flagella motors. Although characterization of the reactions in the chemotaxis
signaling pathway is sufficiently complete to construct computer simulations that predict
the phenotypes of mutant strains with a high degee of accuracy, two previous
experimental investigations of the activity remaining upon genetic deletion of multiple
signaling components yielded several contradictory results [CoNey et al., J. Bacteriol.
17I, 5190 (1989); Liu & Parkinson, Proc. Natl. Acad. Sci. USA 86, 8703 (1989)]. For
example, "building up" the pathway by adding back CheA and CheY to a gutted strain
lacking chemotaxis genes resulted in counterclockwise flagellar rotation, whereas
"breaking down" the pathway by deleting chemotaxis genes except cheA and cheY
resulted in alternating episodes of clockwise and counterclockwise flagellar rotation. Our
computer simulation predicts that trace amounts of CheZ expressed in the gutted strain
could account for this difference. We tested this explanation experimentally by
constructing a new deletion of the che genes that cannot express CheZ and verified that
the behavior of strains "built-up" from the new deletion does in fact conform to both the
phenotypes observed for "break-down" strains and computer-generated predictions. Our
findings consolidate the present view of the chemotaxis signaling pathway and highlight
the utility of molecularly-based computer models in the analysis of complex biochemical
networks.
[This work was very recently published in J. Bacteriol. 180, 3757 (1998)]
LACK OF STANDARDIZATION OF ANYALYTICAL TECHNIQUES
AND INFORMATION I:IANDLIaNG AFFECTS THE ADOPTION
OF GENETIC DATA IN CLINICAL TRIALS AND THE CLINIC.
M. B_,vwater
Perkin-Elmer/Genscope, 50 Danbury Road, Wilton, CN 06897
E._. _1!: Mbywater @ genscoFe.com
Although the promise of molecular biology has been the era of Molecular
Medicine, the translation of research observations into clinical facts has taken longer than
many scientists have optimistically predieted.
With the advances made in Genomics, identification of inherited waits associated
with susceptibility to disease have increased awareness in the medical field of the power
of genetic information. Inherited genetic markers as well as genetic mutations are
assigned the potential of either being disease causing or indicators of disease progression
or response to therapeutic agents.
The acceptance of these research results into clinical trials is hampered by the
lack of robust results now generated by a variety of non-standardized technologies, and
the lack of links to give function of biological pathways.
This results in data, which is not acceptable as parameters in clinical trials.
Confusing evidence also hampers the clinical adoption of genetic markers as new
standards of care for the management of disease.
A common language and standardized interpretation of results will provide a basis
to simulate clinical trials using computed information. Several sources ultimately
resulting in the use of molecular information to streamline protocols. These demands
impose new challenges for companies providing tools for such studies and impact the
business models currently available.
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INTEGRATING BIOINFORMATICS, DATA, AND BIOLOGISTS.
J. M. Cherry
S tanford University School of Medicine, Department of Genetics, Medical Center,
Room M341, Stanford, California 94305-5120
Voice: 650-723-7541 FAX: 650-723-7016 email: cherry@genome.stanford.edu
We are working to build better databases, enhance the predicted information with
experimental results from the literature, provide access to the large scale results but also
provide summaries of these results to facilitate greater availability within the greater
scientific community. The ability to make appropriate inferences from the wealth of
systematic genomic sequence, expression, two-hybrid and other large scale projects
requires a solid base of biological information. The data must be maintained and
distributed in a manner that enhances scientific discovery. Computed predictions of
biological function provide a wealth of useful information. These hypothetical
statements are even more powerful if associated with experimental results. Within the
Department of Genetics at Stanford a diverse group of experts has been assembled. Here
is a brief list of projects I am managing. 1) The Saccharomyces and Arabidopsis
databases are collecting a variety of information from individual laboratories and from
large functional genomic projects. 2) A database and associated software is being created
for the analysis of DNA microarray results. 3) A shared classification or grouping
system is being developed with other database groups to facilitate querying in a uniform
manner across different species databases. This network of biological processes will
include a common vocabulary and be used by the databases to categorize an organism's
gene products. 4) Finally, we are analyzing the integrated data from DNA microarray
experiments from Saccharomyces to identify expression control elements.
BUILDING UPON MOLECULAR PROFILING:
CREATING TECHNOLOGY PLATFORMS THAT WILL REVOLUTIONIZE
CANCER DETECTION, DIAGNOSIS AND TREATMENT.
C. A. Dahl
National Cancer Institute, Building 31, Room i 1A03,
31 Center Drive, MSC 2590, Bet_esda, MD 20892-2590
Phone: (301)496-1550 Email: carol dahl@nih.gov
The Challenge: It has become clear that cancer is a set of diseases that result
from changes in the genome and the expressed products of the genome. The pathway of
technological opportunity resulting from this fundamental observation can have profound
impact on the management and prevention of cancer.
The first step in this pathway requires defining the molecular profiles of cancer.
To this end the National Cancer Institute (NCI) has launched an initiative, the Cancer
Genome Anatomy Project (http://www.ncbi.nlm.nih.gov/ncicgap/), which will provide
both the information and technology infrastructure needed to uncover the molecular
profiles of cancers. Correlation of the molecular profiles with critical characteristics of
cancers, such as prognosis and response to therapy, will provide a foundation for
improved decision-making relative to needs and strategies for intervention and
prevention.
The NCI is now interested in looking beyond these near term goals. Building
upon molecular profiling, we wish to create technology platforms that will revolutionize
cancer detection, diagnosis and treatment. The NCI is interested in identifying technology
systems or components that will enable sensing of molecular alterations in the body in a
way that is highly sensitive and specific, yet non-intrusive. Molecular profile information
would then be transmitted to external monitoring devices that would provide input to the
physician. The technology system should additionally serve as the platform for, or have a
seamless integration with, capabilities for intervention specific for the detected molecular
profile. The capability, for intervention should allow for control and monitoring of the
intervention that will ultimately be under the supervision of the physician.
Achieving this ambitious objective will require the development and integration
of a series of capabilities including highly specific molecular recognition, signaling
capability, controllable intervention capabilities, methods for monitoring intervention
release and impact, and biotolerance. This will require the input and collaboration of
investigators from a variety of disciplines, many of which have not traditionally engaged
in cancer research.
Current approaches to cancer detection and diagnosis tend to be highly invasive
and inadequately informative with regard to the underlying molecular basis of the
specificdisease.Therapiesrangefrom dramaticallyinvasiveprocedures,suchassurgery,
to theadministrationof relativelytoxic agents,suchaschemotherapyandradiation.
Ultimatelypatientswouldbenefitfrom theavailabilityof non-invasiveapproachesto
cancerdetectionanddiagnosislinkedto minimallydebilitatingtreatmentsthatare
tailoredto targettheprecisemolecularalterationsin the individualtumor.
Thedevelopmentof platform technologiesthatenablenon-intrusivesensingand
interventionin theindividual will revolutionizetheclinical approachto detection,
diagnosisandtreatment.Suchsystemscouldallowdetectionandelimination_f cancer
cellsin their earlieststages.Theywould forestallthedevelopmentof very largetumors
andwouldmovemeaningfulinterventionto amuchearlierpoint in thepathof
progression.Thiswill minimize patientinconvenienceandincapacitation,andallow
detection,diagnosis,andtreatmento bec!oselycoupled,enablingeffective
administrationin asingle,seamlessprocess.SendYour Ideas!
TheNCI is inviting membersof theacademic,governmentandindustrialresearch
communitiesto provideinput thatwill contributeto definingthegeneralscopeof aBroad
AgencyAnnouncementrequestfor contractsin late1998or early 1999.Input is
encouragedin theform of white papers,but will alsobeacceptedin alternativeinformal
written formats.Interestedpartiesareencouragedto provideinformationonnewareasof
technologicalopportunitythatcouldspeedprogresstowardthescientificgoalsstated
above.
ELECTRON TRANSFER IN DNA?
THE DESIGN OF A STRUCTURALLY DEFINED SYSTEM
N. L. Frank, E. J. Krider, J. J. Rack, Td. Meade"
Incorporation of metallated nucleosides into DNA at fixed and known locations is
crucial to exarmnztion of electron transfer rates and the variation of these rates with
structure, distance, and position. Electron transfer through DNA may be central to
important biological processes such as DNA damage/repair and synthesis, information
transcription, and DNA-drug interactions. The mechanism, however, of energy and
electron transfer central to these processes is unclear. Interpretation of the results is
complicated by the distribution of distances examined, as well as uncertainty in the
mechanism of charge migration. Recent studies have attempted to examine the rates of
electron transfer in DNA with varying distance by direct intercalation of donor/acceptor
molecules into DNA. The results of such studies have shown a remarkable dependence
of electron transfer rates on the design of the experiment, suggesting that a detailed and
systematic study is needed. We are currently investigating the mechanism of long-range
electron transfer processes in modified oligonucleotides with covalently fixed donors and
acceptors. Novel synthetic methodology has been developed for the site-specific
incorporation of transition metal acceptor-donor complexes into oligonucleotiodes by
solid phase synthesis; in particular, site specific labeling of the ribose moiety.
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DATA INTEGRATION:
THE ISSUE OF STRUCTURE VERSUS FUNCTION.
M. N. Liebman
Bioinformatics, Wyeth-Ayerst Research, R3037, 145 King of Prussia Road,
Radnor, PA 19087
liebmam@war.wyeth.com
The issue of data integration has played a significant rote in the development
and collection of genome sequence data and in raising issues about its integration with
functionally related biological information. This post-genome data integration issue
has typically focused on the use of relational data models because of the size of
component data sets, but we have noted that this can be significantly limiting in
providing the access to complex data inquiries and relationships. A data model which
is more functional than structural is being implemented to integrate genome sequence,
protein structure and function, with higher order data including pathway models,
cellular processes, toxicology, pharmacokinetics and clinical data.
SEEING IS BELIEVING:
MONITORING IN VIVO GENE E,'V_RESSION
BY MAGNETIC RESONANCE IMAGING
A. Y. Louie and T. J. Meade
California Institute of Technology, Division of Biology, Biological Imaging Center, and
the Beckman Institute, Pasadena, CA 91125
MRI offers a non-invasive means to map brain structure and function by sampling
the amount, flow or environment of water protons in vivo. This intrinsic contrast can be
augmented by the use of paramagnetic contrast agents; however, these agents are little
more than anatomical reporters which cari at best label individual fluid compartments or
distinguish tissues that are magnetically similar but histologically distinct. To permit
more direct imaging of the physiological state of cells or organs, we have prepared and
tested a new class of "smart" contrast agents that are activated by [3-galactosidase. The
complexes were tested in Xenopus laevis embryos and provide the first example of direct,
three-dimensional visualization of gene expression by MRI.
GENE EXPRESSION DATA MINING:
MAKING THE CONNECTIONS
G. Michaels
George Mason University, Fairfax, VA 22030-4444
Email: gmichael @ gznu.edu
Several large-scale approaches for generating gene expression data are currently
competing for broad acceptance. We have concentrated on developing informatics and
visualization tools for working with thousands of genes. An analysis of a yeast whole
genome, gene expression experiment will be presented.
DEVELOPING DRUGS TO TREAT
ISCHEMIC DISEASES
G. Miller
Galileo Laboratories, Inc., 935 East Arques Avenue, Sunnyvale, CA
Email: gmiller@ galileolabs.com
94086
Galileo Laboratories, Inc. mission is to develop drugs to treat ischemic diseases
such as heart attack and stroke. The Company's technical focus is on developing
investigative tools to enable the discovery of drugs to treat both the ischemic and
reperfusion components of ischemic injury. Galileo has constructed cell-based model
systems that are representative of how vital organs make and regulate oxygen dependent
energy synthesis. Galileo's cell-based model system approach is inexpensive, fast, robust
in data, and lends itself to complementary drug discovery tools such as genomics,
proteomics, combinatorial chemistry and high throughput screening techniques. The
Company is applying its proprietary Metabolic Target Array Queryti [MTAQ_.] to
identify target sets and therapeutic candidate relevant to ischemic disease, and is
leveraging its MTAQ/i technology in PKADlV_-Toxicology and human medical
nutritionals applications.
Biographical Sketch
Guy Miller, MD, PhD, Chairman and Chief Executive Officer. Dr. Miller is a
founder of Galileo Laboratories, Inc. Prior to founding Galileo, Dr. Miller was an
Assistant Professor at Johns Hopkins University, School of Medicine. Dr. Miller obtained
his PhD in Chemistry under the direction of Professor Sidney Hecht, John Mallet
Professor of Chemistry at the University of Virginia, and his MD at the Medical CoUege
of Pennsylvania. After completing an internship in Surgery at the University of Chicago,
Dr. Miller completed a residency in Anesthesiology & Critical Care Medicine at Johns
Hopkins Hospital, followed by a fellowship in Multidisciplinary Critical Care Medicine.
Currently, he holds an appointment as Clinical Instructor, Stanford University School of
Medicine where he attends patients in the Medical Surgical Intensive Care Unit.
GENE CLUSTERS: AN APPROACH TO FUNCTIONAL
CLUSTERING FOR PROKARYOTICS
R. Overbeek
Argonne National Laboratory
Argonne, IL 60439
Emall: overbeek@mc.anl.gov
The presence of gene clusters on prokaryotic genomes is well recognized. The
origins of these clusters and the role they play is still a topic of discussion. What we have
found is that one can use such clusters to accurately predict functional coupling between
genes. The technique requires the use of numerous genomes to produce reliable coupling
data. Once one has access to 15 - 20 prokaryotic genomes containing a functional
subsystem (e.g., a pathway) it it possible to predict which genes ar3 functionally coupled
(although it is often the case that a complete set of genes for the pathway will not exist
within a single cluster in any of the genomes, and about 65% of the relevant individual
genes within the set of genomes will not be included within clusters). We can now
couple hundreds of "hypothetical proteins" to specific functional subsystems, or in many
cases simply assert that a set of hypothetical proteins together form a functional
subsystem.
A rudimentary analysis reveals that the coupling information grows as the square
of the number of genomes included in the analysis: below about ten genomes, the
number of reliably, inferrable couplings is quite limited, but by the time twenty complete
genomes exist including a given functional subsystem (i.e., pathway) the complement of
genes related to the system is revealed clearly.
We believe that this technology will play a key role in characterizing the genes in
prokaryotes.
INFERENCE OF GENETIC PROGRAMS IN M_4LIAN
CNS DEVELOPMENT AND INJURY
R. Somo_oyi
Incyte Pharmaceuticals, Inc.; 3174 Porter Dr.; Palo Alto, CA 94304
Phone: 650-845-4210 Fax: 650-845-4255 email: rsomogyi@inc-,rte.comBi
Large scale gene expression mapping is motivated by the premise that biological
information is transmitted from gene sequence to gene activity patterns, and, through a
hierarchy of inter- and intraceilular signaling functions, back to the regulation of gene
expression. This process can be conceptualized as a genetic network. In an effort to
understand the output of the genetic network, we have conducted extensive surveys of the
dynamics of gene expression in mammalian CNS development and injury. Analysis of
this data suggests modules of genetic pro_ams that are conserved among CNS regions
(spinal cord and hippocampus), and can be reactivated following injury (kainic acid
induced seizures). These results indicate that more detailed ]top-downi studies of this
kind, coupled with advanced inference techniques, may help resolve the distributed
molecular processes underlying complex genetic signaling networks. Such understanding
will be critical for the discovery and validation of drug targets in CNS pathology.
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_AFTER THE GENOME IV
New Ways to Probe the
Motecules of Life
JACKSONHOLE,WYOMING_Almost 200 years after Lewis and Clark first
glimpsedthe GrandTetons,a posseof about 80 scientistsgathered here from
10 to 14 October for an exploration of their own. At the annual "After the
Genome" meeting, they discussedhow to get from genomic information to
an understandingof biology. Highlightsinclude powerful computer programs
for modeling human diseasesand new techniquesfor protein analysis.
For humans, Halloween is
Making over, and the witches, Mon-
Coats for icas,and Bill Clintons have
Molecules taken home their prizes for
best costume and packed
their gear away until next year. But a team at
the biotech start-up company Alnis, in San
Leandro, California, has devised ingenious
cos_mes for proteins and other molecules
that they could wear all year long.
Alnis's scientific foun-
der, David Soane, and his
colleagues have found a
way of trapping individual
molecules inside polymer
coatings a single molecule
thick. Although the meth-
od is in its infancy, re-
searchers can envision a
wealth of applications for _'_ l
it. "This is a clever idea _
and the method has real
scope" says Alexis Bell, a
chemical engineer at the
University of California,
Berkeley, and an adviser
to the company. The coat-
ings could stabilize na-
ture's biological catalysts,
the enzymes, enabling
them to tolerate organic
solvents and high temper-
atures, and protect thera-
peutic proteins, such as in-
sulin, from digestion so
that they could be taken
by mouth.
Other investigators are
also devising stabilizing
coats for proteins, but the
Alnis method boasts the
advantage that it can be
adapted to a wide variety
of biological molecules and solvent systems.
What's more, because the polymer coats re-
tain the impression of the ta_et molecule's
shape even after it is removed, they could be
used for molecular detection both in the
body and in biological samples, such as
blood or biopsy materials. "It's potentially a
¢,
r. C_:
z
Entrapment. After the coat mol-
ecules bind to specific sites on the
target, they are [inked together.
very, exciting technology, particularly for de-
tecting small molecules and perhaps even
proteins," says Frances Arnold, a chemical
engineer at the California Institute of Tech-
nology in Pasadena.
Soane's method is a twist on molecular
imprinting, a technique that has been around
for several decades. In molecular imprinting,
the target molecules are embedded in a mate-
rial that polymerizes around them to produce
a three-dimensional block
bearing the targets' impres-
sions. The block can be used
for a variety of applications.
By breaking it into chunks,
for example, researchers can
generate a chromatographic
material that grabs onto the
target molecules, allowing
their isolation from complex
mixtures.
Instead of forming a
polymer block, Soane gen-
erates a molecular glove that
perfectly fits a protein or
other molecule. He accom-
plishes this by exposing
the molecule to custom-
designed, polymerizable
building blocks with dis-
tinctive heads and tails. The
heads, for example, may
carry positive or negative
charges that allow them to
bind to oppositely charged
amino acid residues in the
protein, while the tails,
whlcla ate hydrophobic and
tend to congregate with
each other, are designed to
link together.
Once the heads of the
chemical have bound to the
target molecule, Soane uses treatments such
as ultraviolet light to link the chemicals into
a shell, dubbed a synthetic polymer comple-
ment (SPC), around the protein. It's also
possible to construct the SPC coat in such a
way that an enzyme protein retains its cat-
alytic activity. One way of doing this is to
protect the enzyme's catalytic site with a
molecule, such as one of the enzyme's own
substrates, that binds to the site and can be
removed once polymerization is accom-
plished. As a "proof of principle" test,
Soane has shown that an SPC coat made the
enzyme chymotrypsin far more durable at
high temperatures in an organic solvent
while still allowing it to be active.
Soane says that the SPC covering can
also be released from its target molecule, al-
though he won't say how because the tech-
nique is proprietary. If the empty shells then
encounter the molecule again, they can bind
it. He's shown, for example, that empty SPCs
can recognize a small molecule called es-
culin that contains a sugar. Eventually, the
chemical molds might be used for molecular
detection--in effect serving as artificial anti-
bodies that are more stable, cheaper, and
quicker to make than the real thing. For ex-
ample, SPCs linked to tracers that can be de-
tected by ultrasound might help with early,
noninvasive diagnosis of cancer.
"We have the beachhead successes for
the recognition and binding aspects," Soane
says. Still, he adds, "it will be a long time
between now and when a diagnostic or ther-
apeutic discovery is made." But costumes as
good as these seem likely to win a prize or
two eventually, for utility if not for beauty.
Chips for For the past several years,
the fluorescent glow of DNA
Protein chips has signaled a revolu-
Analysis tion in researchers' ability to
detect nucleic acids and
monitor gene activity in living cells. But de-
veloping ways to keep track of the many dif-
ferent proteins in a cell has been much more
difficult. Although techniques like the poly-
merase chain reaction can amplify scarce
DNA into detectable amounts, the tiny con-
centrations of proteins in cell extracts, blood,
and other biological samples can't be boosted
so easily. But a new tool might help with pro-
tein analysis: the ProteinChip technology de-
veloped by scientists at Ciphergen Biosystems
Inc. of Palo Alto, California.
Because the Ciphergen method com-
bines a tiny chip with a "sticky" surface
with the sensitive analytic capabilities of
mass spectrometry, it doesn't require an am-
plification step. Consequently, it is not only
very fast but can be used with small sam-
ples--microliters instead of the milliliters of
conventional methods. "They're tackling
one of the core problems of analyzing pro-
teins: looking at proteins that are present in
very low abundance," says Jeff Wiseman of
SmithKline Beecham Inc. in King of Prus-
sia, Pennsylvania. The method should allow
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scientists to discover new proteins, purify
them, measure their quantities, and discern
their chemical and biological properties, all
with one chip.
The technology is the brainchild of
William Hutchens of Ciphergen and his col-
leagues. The chip, which is about a millimeter
across, holds some kind of molecular bait--
antibodies, carbohydrates, receptors, or any of
a wide variety of smaller synthetic chemi-
cals--4.hat can trap many different proteins at
once. To perform an analysis, a researcher ap-
plies a sample to a chip, lets the proteins ad-
here to it, and then washes away anything that
doesn't stick.
In the next step, a laser
zaps the chip surface with
just enough energy to
break noncovalent bonds
and release the proteins.
An electric field shoots
these proteins to the detec-
tor of a mass spectrometer,
which reads out their
molecular weights. (The
company calls the process
Surface-Enhanced Laser Desorption//oniza-
tion or SELDI.)
Knowledge of the chemical nature of the
molecular bait combined with the molecular
weights of the proteins permits one particu-
larly useful analysis: producing fingerprints
of the protein composition of samples con-
raining hundreds or thousands of proteins.
By comparing closely related samples--
blood serum from a healthy person and
from someone with a disease, for example,
or extracts of dividing and nondividing
cells--scientists can detect changes in the
amounts and types of proteins.
According to John Quackenbush, a
molecular biologist at The Institute for Ge-
nomic Research in Rockville, Maryland,
such changes can provide valuable clues to
which chores the proteins are performing. In
one set of experiments, for example, he com-
pared the protein content of dividing and
nondividing cells of the bacterium Haemo-
philus influenzae. The analysis picked up 600
of the 1740 proteins thought to be encoded in
the H. influenzae genome, and for about 30
to 60 of them, the amount varied under the
two conditions. "It's pretty extraordinary to
be able to sit down and, in the course of a few
hours, get information about 600 distinct pro-
teins" Quackenbush says.
Once an interesting protein is identi-
fied-say, one that is made in large amounts
in dividing cells but not in quiescent cells--
the chips can be used to characterize, iso-
late, and even sequence it. By systematically
testing different combinations of wash con-
ditions and chip materials, researchers can
use SELDI to explore the properties of a
protein, such as how strongly it adheres to a
surface with positive charge and whether it
binds a particular metal ion. Furthermore,
Ciphergen's computer programs can identify
the combination of surface and wash condi-
tions under which the protein of interest has
the fewest neighbors, opening the way to
purifying the protein.
Scientists can sequence the protein on
the chip by exposing it to enzymes that re-
lease its peptides one by one, so that they
can be analyzed by mass spectrometry. Con-
ventionaiiy, i-iatchens says, different tools
had to be used for each step from discover-
A shade of difference. The heights of the lines indicate the
amounts of specific proteins in diseased (orange) and normal
(blue) cell
II1 ili,Jil,,,,i I
ing a protein to isolating and characterizing
it. But with SELDI, he adds, "you use exact-
ly the same chip [for all three steps]?'
Companies developing
C o m p u t e r new drugs usually face a
Models for great leap into the un-
DrugTesting known when they move
from test tube and animal
studies into clinical trials. Given that it takes
at least $20 million just to get a drug into hu-
man efficacy tests, failures can be expensive.
One critical choice comes early: which of the
many disease-related molecules should be tar-
geted. "If you don't make the right choice of
drug target at the beginning, you can really
have a big mistake at the end," says Robert
Dinerstein of Hoechst Marion Roussel Inc. in
Bridgewater, New Jersey. Now scientists at
Entelos Inc. in Menlo Park, California, are
trying to reduce the guesswork by simulating
diseases---and the molecular interactions that
underlie them--in a computer.
At the meeting, Tom Paterson of Entelos
reported that the company had so far built
models for three common diseases: asthma,
obesity, and HIV/AIDS. Each one seeks to
combine what's known about the molecular
and cellular changes leading to the disease
with the symptoms it causes. The Entelos
system "links the basic processes to their
consequences in the entire system," says
Dinerstein, who has used the asthma pro-
gram in his work on respiratory diseases.
"That hasn't been done before?'
Using these programs, researchers can
conduct virtual experiments to pretest drugs,
modeling what happens when a drug alters
the activities of a specific molecule. So far
the models have helped pharmaceutical
companies develop new hypotheses about
mechanisms of disease and evaluate existing
and novel therapeutic approaches.
To construct the models, the Entelos team
formulates mathematically based hypotheses
about how all the components in the disease
system interact. With asthma, for example,
they incorporate what is known about the role
of inflammatory cells and the factors they
make and respond to in constricting the
respiratory airways. The researchers then tune
the math and the relationships between the
different parts of the model until it accu-
rately reflects the way the disease behaves.
The simulation can then show what hap-
pens to any one component of the system
in response to a change in another part of
it---caused, say, by administering a drug or
exposing the airways to allergens. "There's
nothing quite this comprehensive," says
one of Entelos's scientific advisers, bio-
engineer Douglas Lauffenburger of the
Massachusetts Institute of Technology.
Dinerstein tested the asthma simulation
by seeing how it responds to existing drugs.
He found in the model exactly what compa-
riles had learned from clinical trials: Effective
drugs decrease airway resistance, while inef-
fective drugs, including some that companies
had pursued quite aggressively, don't.
Using the asthma program, Dinerstein's
group also carried out a virtual experiment
in which they blocked the activity of a cer-
tain inflammatory factor to see if it might be
a good target for an inhaled form of therapy.
The next asthma attack was worse because
another part of the body was compensating
for the decreased inflammatory response.
"We hadn't really thought about the rebound
effects," says Dinerstein.
In addition, the software provides informa-
tion management tools with quick connec-
tions to the literature references and the math-
ematics on which a given part of the model
rests. Researchers can also incorporate their
results into the program and chronicle the
evolution of their thinking.
Different parts of the model vary in relia-
bility, depending on the information available.
But as Dinerstein notes, even the gaps can
help because they point out where researchers
should direct their studies. Now that scientists
are investing a large effort toward f'mding the
sequence and function of all the human genes,
such models are badly needed, says Lauffen-
burger. "The promise of this whole new field
of molecular medicine requires that we get an
idea of the consequences of molecular alter-
ations. Until you can put together models like
this, it's all pretty much guesswork?'
"-EVELYN STRAUSS
Evelyn Strauss is a writer in Berkeley, California.
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induces a different feeding structure named
syncytium. While Mi resistance results in
localized tissue necrosis, no such hypersen-
sitive reaction is observed with HsF". As
judged from sequence analysis, Hsl _' is
also is part of a signal cascade, but seems to
be located in the plasma membrane whereas
Mi is cytoplasmic.
These findings have two major implica-
tions for future breeding strategies and on
our understanding of host-pathogen inter-
actions. At first glance, it seems puzzling
that one gene causes resistance to species
that obviously have nothing in common
except that both make use of their stylets to
feed from the host tissue. However, the
aphid inserts its stylet intercellularly to feed
from the phloem, whereas the nematode
penetrates the cell membrane with its stylet
to take up nutrients from inside the cell. As
it is extremely unlikely that the Mi protein
reacts with the same ligand on nematodes
and aphids, it cannot be the primary recep-
tor, and probably partakes in an intracellu-
lar signal transduction cascade that starts
with ligand binding to yet unknown recep-
tors and ends with the activation of defense-
related genes within the nucleus that ulti-
mately results in localized cell death.
The prospects for breeding new disease
resistant tomato varieties are immediate,
and it is tempting to think of transforming
unrelated crop species that are attacked by
aphids and root knot nematodes. Some
caveats, however, would urge caution in the
implementation of this attractive strategy. It
seems unlikely that Mi will be effective
against cyst nematodes because of the lack
of homology to the Hsl'" Eerie. Also, breed-
ers must be aware of resistance breaking
aphids frequently evolving from the huge
number of individuals in the field. One such
isolate has already been shown to break the
Mi resistance in Motelle and transgenicsL As
Mi resistance follows a one-to-one relation-
ship, in which a virulence gene of the
pathogen matches a resistance gene from
the host single, mutational events can result
in virulent isolates that pose a threat to all
varieties.
i. vos, P. et alNa198_technoL 16:1365-1369.
2. Rossi, M. et al .PflcE88%L3tl. Acad. ScL USA
95:9750-9754.
3. Milliagan, S.B. et al. Plar_98Cell
10:1307-1319.
4. Kaloshian, I . et al A4ot9_sn. Genet.
257:376-385.
5. Messeguer, R. et al. _ App[. Genet.
82:529- 536.
6. Jones, J.D.G. 19_dfT. Opio. BJotech_ol.
7:155-160.
7. Cai, D. et aI.S(_'0BOe275:832-834.
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Modeling the oddities of biology
Bijal Trivedi
During the opening session of "After The
Genome IV"*--a conference recently con-
vened to discuss future directions for
research following completion of the human
genome sequence--Stephen Grand, chief
technology officer of CyberLife Technology
(Cambridge, UK), told the audience about
his perfect pets or "horns." These are cute,
furry, haploid, computerized "creatures,"
with about 400 genes, reproducing via meio-
sis, with chromosomes that align and
crossover, creating duplications, deletions,
and mutations. After random destruction of
one genome, they have viable offspring.
Norns are one of the more sophisticated
attempts to model life processes based on
information at the genetic level. They are
able to learn as their neural networks become
reinforced by neurotransmitters---which
punish and reward as they interact with their
environment--and they eat, sleep, age, and
suffer from disease similar to their biological
brethren. They are also an extreme example
of an unconventional interdisciplinary
approach to biology "after the genome"
The conference of the same name
attempted to initiate and foster collaborations
between researchers from academia and
industry, and to introduce them to govern-
ment officials and representatives from phil-
anthropic organizations who hold the purse
strings and the power to trigger change at the
institutional level. Although representatives
from the latter two groups were few, the eclec-
tic mix of researchers--biologists, physicists,
mathematicians--interacted with each other
with the initial awkward anticipation of
Figure 1. An MRI image tracing gene
expression in the Xenopus embryo, as
reported at the meeting•
courtship: Few expected a "grand unified pro-
ject" to emerge because of the diverse spec-
trum of expertise, but many found the expo-
sure to different fields refreshing. Several ini-
tiated new collaborations.
Three presentations, which were univer-
sally well received, all emphasized modeling.
Thomas Paterson of Entelos (Menlo Park,
CA) presented a software package for simu-
lating complex disease states such as asthma
and obesity. This method of disease analysis
takes a "top down" approach, pinpointing
the most debilitating clinical aspects of a dis-
ease and then searching for the cellular, mol-
ecular, and environmental mechanisms
involved.
The most ambitious aspect of the soft-
ware is that it attempts to integrate clinical,
physiological, biochemical, and genotypic
data into a graphical interface of bubbles and
arrows. The interface masks an underlying
mathematical infrastructure that specifies
precise relationships between molecular
species and dynamic processes.
The models assume that cellular processes
constantly strive to keep the cell in a homeo-
static state. When certain parameters are
exceeded, disease may ensue. A global
overview of a disease makes it possible to
uncover synergies that otherwise remain
invisible when pathways and processes are
studied in isolation. The software is designed
to help pharmaceutical companies determine
drug targets and simulate the downstream
ramifications of specific drug mechanisms.
This should allow them to simulate drug
interactions within a healthy system, before
they conduct extensive clinical or laboratory
experiments.
In another talk, Drew Endy, now at the
Molecular Sciences Institute (Berkeley,
California), and Ian Molineux of the
University of Texas at Austin, described work
attempting to simulate a relationship
between the genetic architecture and fitness
of an organism, and then testing the results
in the laboratory. Endy chose as his study sys-
tem the venerable bacteriophage T7--a virus
for which there is now available full sequence
data on 122 genes and regulatory regions and
extensive information on the bacterial meta-
bolic pathways in which they participate.
Taking the 20 most essential T7 genes,
Endy "slid" them back and forth along the
genome and looked for the simulated effects
of gene position on the viability of the phage.
After simulating the effects of moving the
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RNA polymerase to three different positions
in the genome, he then went back to
Molineux, and created the corresponding
strains ofT7 in the laboratory.
The model predicted that two of these
strains of phage would grow more slowly than
wild type, whereas the third would grow
faster. Laboratory data showed that the model
was indeed correct for the first two strains,
but incorrect for the third, as the last strain
grew slower than wild type. Thus, compari-
son ofT7 phage's simulated growth rate with
that of the actual strains provided a measure
both of the strength of the model and of cur-
rent understanding of T7 biology. When the
experimental biology does not match the
simulation, it telegraphs that a piece of the
biological puzzle remains to be found.
Further work should be directed toward
ascertaining whether such information can
be used to design "fitter" organisms or differ-
ent genomes for different functions. An obvi-
ous application would be to design better
vectors for gene/drug therapy.
More immediate in its application was an
impressive demonstration by Thomas Meade
from the California Institute of Technology
(Pasadena, CA) of real-time, three-dimen-
sional visualization of gene expression using
magnetic resonance imaging (MRI). This
MR/technology uses "smart" contrast agents
that provide anatomical information and
also reveal the metabolic status of the cell.
In MRI, a magnetic field orders the major-
ity of hydrogen nuclei within an organism to
align with, rather than against, its direction.
Pulsing radio frequencies then induce a spin
flip in the nuclei of hydrogen atoms. When
the radio pulse is removed, the nuclei return
to their original state, emitting a radio wave.
The time taken to return to the unexcited
state is called the relaxation time, which is
inversely proportional to the intensity of the
image created by the computer. An agent that
can decrease the relaxation time thus increas-
es the local intensity of the image. Atoms with
unpaired electrons are able to reduce the
relaxation time; this is why gadolinium, an
ion with seven unpaired electrons, is com-
monly used as a clinical contrast agent.
Meade's group has created a compound in
which the gadolinium ion is masked by an
enzyme substrate. When the enzyme is pre-
sented, the substrate is cleaved and the
gadolinium ion is exposed and free to inter-
act with nearby hydrogen nuclei. These sub-
strate masks are enzyme-specific and can
trace the activity of individual genes during
the development of an organism.
Meade's team presented data obtained
after injecting the gadolinium contrast agent
into both halves of the two-cell stage of a
Xenopus embryo. At the 16-cell stage, mRNA
for [3-galactosidase was injected into one cell
that was known from developmental fate
maps to differentiate into the left dorsal
notochord. An MRI image of the live organ-
ism showed that only the left dorsal noto-
chord was lit up, indicating that the gadolini-
um had been "turned on" only in cells con-
taining the mRNA (see Fig. 1.)
The ability of the technology to differenti-
ate metabolic states of cells suggests many
potential clinical applications. The contrast
agents may also provide a tool for under-
standing the pattern of development at the
level of temporal gene expression.
Perhaps by 2010, biology will, in fact,
have reached the end of the reductionist
road, and efforts will be largely directed at
reassembling the pieces that took more than
halfa century to dissect into a more compre-
hensible whole. In such an environment,
meetings like this will become more fre-
quent, especially if the various computer
simulations promising to predictively inte-
grate genetic sequence, expression, and phys-
iological data begin to make good on their
promises.
*Jackson Lake Lodge in Jackson Hole, WE,
October 10-14, 1998.
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